PremaPPeethambaramMDAssociate Professor

PubMed

• Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience.
  Nusrat Jahan, Jodi Taraba, Nicholas J Boddicker, Karthik V Giridhar, Roberto A Leon-Ferre
  Clinical Breast Cancer. 2024-10-17
• Participant Evaluation of a Multi-disciplinary Oncology Preceptorship Training Program for Oncology Health Professionals from Kumasi, Ghana.
  Kenneth W Merrell, Thomas Okpoti Konney, Osei Acheamfour, Joseph Lucido, Abena Yeboah Aduse-Poku
  Journal of Cancer Education. 2024-08-01
• Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial.
  Tufia C Haddad, Vera J Suman, Karthik V Giridhar, Kostandinos Sideras, Donald W Northfelt
  Clinical Cancer Research. 2024-08-01

Journal Articles

• Soyfood consumption in breast cancer survivors: Don't overstate the facts!  
  Peethambaram P, Olson J, Loprinzi CL, Oncology, 1/1/2013
• Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival  
  Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duv..., Ann Oncol, 4/1/1999
• Toxicity of systemic adjuvant chemotherapy for colorectal cancer  
  Peethambaram PP, O'Connell MJ, Seminars in Colon & Rectal Surgery, 1/1/1996
• Long-term functional results and complications after combined modality adjuvant therapy for rectal carcinoma  
  Kollmorgen CF, Peethambaram PP, Wolff BG, Seminars in Colon & Rectal Surgery, 1/1/1996
• Join now to see all

Books/Book Chapters

• Supportive Care in Cancer: A Handbook for Oncologists 
  Chapter: Management of cancer anorexia and cachexia. 
  Page 297 - 308Peethambaram PP, Loprinzi CLEditors: Klastersky J, et al.Marcel Dekker, Inc., New York, NYEdition 2nd,1999
• Principles and Practice of Supportive Oncology 
  Chapter: Cancer anorexia/cachexia. 
  Page 133 - 139Loprinzi CL, Goldberg RM, Peethambaram PPEditors: Berger A, et al.Lippincott-Raven Publishers, Philadelphia1998

Abstracts/Posters

• Phase i dose-escalation and drug interaction study of abt-888 (parp1 inhibitor) and topotecan (topoisomerase I inhibitor) in patients with advanced cancer.
  Boakye-Agyeman F, Reid J, Menefee M, Buhrow S, Walden C, Piens J, Kayode O, Erlichman C, Haluska P, Northfelt DW, Kaufmann SH, Ames M, Satele DV, Tang H, Peethambaram ..., Clin Pharmacol Ther, 3/1/2014
• Results from two phase 1 trials of HER2/NEU-directed active cellular immunotherapy in patients with advanced malignancies.
  Sims RB, Park JW, Peethambaram PP, Melisko M, Rinn KJ, Alberts SR, Provost NM, Ann Oncol, 10/1/2010
• Phase II trial of lapatinib in combination with weekly topotecan in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
  Haluska P, Oberg AL, Dakhil SR, Ziegler KLA, Rowland KM, Hartmann LC, Moore DF, Keeney GL, Peethambaram PP, Ann Oncol, 5/1/2009
• A phase 2 trial of flavopiridol and cisplatin in platinum-resistant ovarian cancer.
  Peethambaram PP, Burton JK, Oberg AL, Gomez-Dahl LC, Isham CR, Tibodeau JD, Chomjak TL, Colevas AD, Wright JJ, Erlichman C, Bible KC, Molecular Cancer Therapeutics, 12/1/2007
• Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients.
  Galanis E, Hartmann LC, Cliby W, Zollman PJ, Peethambaram PP, Long HJ, Kaur JS, Sloan JA, Peng KW, Russell SJ, J Clin Oncol, 6/1/2006
• An open-label study of autologous dendritic cells loaded with escalating doses of Her500hGM (APC8024) in patients with treatment refractory metastatic tumors that over...
  Prema P. Peethambaram, MD, ASCO, New Orleans, LA, 6/1/2004
• A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer.
  Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Peethambaram P, Hanson LJ, Erlichman C, Cheng S, Proc Am Soc Clin Oncol, 1/1/2004
• Immunotherapy targeting HER2/Neu: results from Phase I studies of APC8024 in women with metastatic breast cancer.
  Melisko ME, Peethambaram P, Rinn K, Jones LA, Sims RB, Park JW, Breast Cancer Res Treat, 1/1/2004
• A phase I trial of topotecan combined with cyclophosphamide and carboplatin with autologous blood stem cell transplant for the treatment of relapsed or persistent ovar...
  Peethambaram P, Litzow M, Safgren S, Hartmann L, Barrette B, Long H, Suman V, Reid J, Ames M, Kaufmann S, Proceedings of ASCO, 1/1/2003
• A phase I study of sequential gemcitabine and MTA (LY231514) in patients with advanced malignancies.
  Adjei A, Erlichman C, Pitot H, Sloan J, Goldberg R, Peethambaram P, Hanson L, Reid J, Johnson R, Eur J Cancer, 9/1/1999
• Serum IL-10 and cure of Hodgkins disease.
  Kliche KO, Viviani S, Notti P, Medeiros LJ, Peethambaram P, Tucker S, Preti A, Witzig T, Bonadonna F, Sarris AH, Onkologie; Annual Meeting of the German and Austrian Society for Hematology and Oncology, Jena, Germany, October 3-6, 1999, 1/1/1999
• A Phase I trial of MTA (multi-targeted antifolate, LY231514) and gemcitabine (Gemzar) in patients with locally advanced or metastatic cancer.
  Erlichman C, Adjei A, Sloan J, Pitot H, Goldberg R, Peethambaram P, Alberts S, Galanis E, Hanson L, Reid J, Rubin J, Burch P, Thornton D, Walling J, Program/Proc Am Soc Clin Oncol, 1/1/1999
• Serum IL-10 and progression-free survival (PFS) in hodgkins disease (HD) patients (PTS) treated only with radiotherapy (RT).
  Sarris AH, Viviani S, Bonfante V, Nadali G, Kliche KO, Micheletti M, Notti P, Peethambaram P, Preti A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez A, Chilosi M..., Blood, 1/1/1999
• Serum IL-10, EBV latency and cure of Hodgkins disease.
  Sarris AH, Viviani S, Bonfante V, Kliche KO, Herling M, Khorana S, Notti P, Medeiros LJ, Peethambaram P, Hagemeister F, Cox R, Tucker S, Preti A, Witzig T, Bonadonna G..., Genes and Immunity, 1/1/1999
• sCD30, progression-free survival (PFS), and survival (SURV) in hodgkins disease (HD) patients (PTS).
  Nadali G, Sarris H, Viviani S, Bonfante V, Micheletti M, Notti P, Peethambaram P, Preti A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez A, Tsimberidou M, Chilos..., Blood, 1/1/1999
• Serum interleukin 10(IL-10) and failure free survival (FFS) of adult Hodgkin's disease (HD).
  Prema P. Peethambaram, MD, The Fourth International Symposium on Hodgkin's Lymphoma, Koln, Germany, 3/1/1998
• Serum interleukin-10 (IL-10) and failure-free survival (ff) of adult Hodgkin's disease (HD).
  Harris AH, Kliche KO, Peethambaram P, Preti A, Jackow C, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Duvic M, Witzig T, Andreeff M, C..., Leuk Lymphoma, 1/1/1998
• A prognostic model for Hodgkin's Disease based on IL 10.
  Sarris AH, Viviani S, Bonfante V, Kliche KO, Notti P, Peethambaram PP, et al, Blood, 1/1/1998
• Cancer, anorexia, and cachexia.
  Peethambaram PP, Central Line, 1/1/1998
• Primary chemotherapy followed by reduced dose radiation for central nervous system germ cell tumors.
  Buckner JC, Peethambaram PP, Smithson WA, Groover RV, Schomberg PJ, Kimmel DW, Raffel C, O'Fallon JR, Shaw EG, J Neuro-Oncology, 1/1/1998
• Phase II trial of primary chemotherapy followed by reduced dose radiation for CNS germ cell tumors.
  Buckner JC, Peethambaram PP, Smithson WA, et al, J Neuro-Oncol, 1/1/1998
• A prognostic model for Hodgkin's Disease based on IL 10.
  Prema P. Peethambaram, MD, American Society of Hematology, 1/1/1998
• Interleukin-10 as a prognostic factor for Hodgkin's disease treated with ABVD: results from MD Anderson and Mayo Clinic.
  Sarris AH, Klilche KO, Peethambaram PP, Witzig TE, Andreeff M, Cabanillas F, Blood, 11/1/1997
• Interleukin-10 as a prognostic factor for Hodgkin's disease (HD) treated with ABVD: Results from MD Anderson and Mayo Clinic.
  Prema P. Peethambaram, MD, American Society of Hematology, 1/1/1997
• Acquired Glanzmann's thrombasthenia (GT) in a patient with chronic large granular lymphocytic leukemia (CLGLL).
  Peethambaram PP, Okuno SH, Daniels TM, Litzow MR, Nichols WL, Blood, 11/15/1995
• Join now to see all

Lectures

• Androgens and anti-androgens to treat breast cancer. 
  Rochester, MN - 3/1/2013
• The "pain" truth about aromatase inhibitors. 
  Rochester, MN - 5/1/2012
• "Journal club" 
  Rochester, MN - 8/1/2011
• Oncotype DX in node positive breast cancer. 
  Rochester, MN - 4/1/2009
• Medical management of gynecologic cancers. 
  Rochester, MN - 10/1/2008
• Chemotherapy, gemcitabine, and etoposide. 
  Rochester, MN - 4/1/2008
• Phase II trial of Flavopiridol combined with cisplatin in ovarian cancer. 
  Rochester, MN - 9/1/2007
• EGFR positive breast cancer. 
  Rochester, MN - 5/1/2007
• Responding to allergic reactions with taxol chemotherapy. 
  Rochester, MN - 1/1/2005
• ASCO updates on gynecologic cancers. 
  Rochester, MN - 8/1/2004
• Chemotherapy for ovarian cancer. 
  Rochester, MN - 11/1/2001
• Ovarian cancer. 
  Albert Lea, MN - 1/1/2000
• Update in treatment of ovarian cancer for internists. 
  Austin, MN - 1/1/1999
• "Primary chemotherapy followed by reduced dose radiation for central nervous system germ cell tumors" 
  3/1/1998
• Inherited breast and ovarian cancer. 
  Black Hills, SD - 1/1/1998
• Recent advances in systemic therapy for ovarian cancer. 
  Rochester, MN
• Join now to see all